Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis.
In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.
Under the terms of the agreement, Abbott will receive worldwide exclusive rights to develop and commercialize elagolix and all next-generation GnRH antagonists for women’s and men’s health.
Abbott will make an upfront payment of $75m and will fund all ongoing development activities. Neurocrine is eligible to receive additional milestone payments of approximately $500m from Abbott for the achievement of certain development, regulatory and commercial milestones; funding for certain internal collaboration expenses; plus royalty payments on any future product sales.
John Leonard, MD, senior vice president of pharmaceuticals and R&D at Abbott, said: “Extensive preclinical and clinical experience with elagolix suggests this drug could be an important advance for women with endometriosis and uterine fibroids, highly prevalent conditions where there is a need for new treatments. This agreement enhances Abbott’s late stage pipeline, with the potential for additional compounds in earlier stage development.”
Kevin Gorman, president and CEO of Neurocrine Biosciences, said: “Abbott shares our long-term vision for elagolix, and, together, we look forward to bringing this important new treatment option to endometriosis and uterine fibroid sufferers.”